

Table S3. Contingency table for infection events during once daily PrEP with 300mg TDF

Inoc. size	Adherence				
	20%	40%	60%	80%	100%
1	(1927;73)	(1954;46)	(1959;41)	(1953;47)	(1952;48)
5	(1668;332)	(1720;280)	(1755;245)	(1768;232)	(1794;206)
20	(1046;954)	(1170;830)	(1274;726)	(1287;713)	(1323;677)
100	(154;1846)	(255;1745)	(312;1688)	(346;1654)	(337;1663)
	p < 0.01 ⁺⁺⁺	p < 0.01 ⁺⁺⁺	p < 0.01 ⁺⁺⁺	p < 0.01 ⁺⁺⁺	p < 0.01 ⁺⁺⁺

Predictions are based on 2000 'virtual patients' simulations respectively. The first number in the brackets in columns 2-6 indicates the number of 'virtual patients' that remained uninfected after viral challenge, whereas the second number indicates the number of patients that became infected. For example when 20% of once daily 300mg TDF pills are ingested and patients are challenged with inoculum size one (one virus reaches a target cell environment) 1927 'virtual patients' remained uninfected, whereas 73 became infected. ⁺⁺⁺ Inoculum size has a significant impact on the number of infections at the p < 0.01 level (χ^2 -test).